Patents Assigned to Genentech
  • Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
    Patent number: 7576187
    Abstract: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of ?SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Samuil Umansky, Hovsep Melkonyan
  • ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20090202536
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: December 2, 2008
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Compositions and methods for treatment of microbial disorders
    Publication number: 20090202475
    Abstract: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.
    Type: Application
    Filed: November 7, 2008
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: Alexander R. Abbas, Nico P. Ghilardi, Zora Modrusan, Dimitry M. Danilenko, Frederic J. De Sauvage, Wenjun Ouyang, Patricia A. Valdez, Yan Zheng
  • COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
    Publication number: 20090202546
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Application
    Filed: January 28, 2009
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: REED J. HARRIS, PAUL A. MOTCHNIK
  • BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO B-CELL ANTAGONISTS
    Publication number: 20090204489
    Abstract: Methods and assays examining expression of one or more biomarkers in a sample are provided for predicting or indicating the effectiveness of treatment of a rheumatoid arthritis (RA) patient with a B-cell antagonist. Methods are provided for identifying patients whose RA is likely to be responsive to anti-RA therapy using a B-cell-antagonist. Methods for treating such patients with B-cell antagonists that incorporate the above methodology are also provided. Further provided are kits and articles of manufacture useful for such methods.
    Type: Application
    Filed: April 1, 2008
    Publication date: August 13, 2009
    Applicant: GENENTECH, INC.
    Inventors: TIMOTHY BEHRENS, THARAKNATH RAO
  • Methods and compositions for selective modulation of vascularization
    Patent number: 7572447
    Abstract: The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: August 11, 2009
    Assignee: Genentech, Inc.
    Inventors: Mary E. Gerritsen, Jo-Anne S. Hongo, Constance H. Zlot
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090196876
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes.
    Type: Application
    Filed: October 18, 2005
    Publication date: August 6, 2009
    Applicant: Genentech, Inc.
    Inventors: Fred de Sauvage, Dorothy French, Lino Gonzalez, Asja Praetor, Weilan Ye, Katherin E. Combs, Zhiyong Ding, Allison Anne Byers Horner, Erin Marie Massey, Charles Montgomery, Laurie Jeanette Minze, Carolina Rangel, Tracy Ellen Willis Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel
  • Treatment with anti-VEGF Antibodies
    Publication number: 20090191215
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: March 31, 2009
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • OMI PDZ MODULATORS
    Publication number: 20090192289
    Abstract: The invention provides modulators of Omi PDZ-ligand interaction, and methods of identifying and using these modulators.
    Type: Application
    Filed: November 13, 2008
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Sachdev S. Sidhu, Yingnan Zhang
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20090191209
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • DcR3 polypeptide, A TNFR homolog
    Publication number: 20090191184
    Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
    Type: Application
    Filed: October 14, 2008
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jin Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
  • PRO4977 polypeptides
    Patent number: 7566774
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: July 28, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • WNT-regulated cytokine-like polypeptide and nucleic acids encoding same
    Patent number: 7566536
    Abstract: The present invention provides novel polypeptides, termed FCTRX polypeptides, as well as polynucleotides encoding FCTRX polypeptides and antibodies that immunospecifically bind to an FCTRX or a derivative, variant, mutant, or fragment of an FCTRX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FCTRX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: July 28, 2009
    Assignees: CuraGen Corporation, Genentech, Inc.
    Inventors: David P. Andrew, David A. Lewin, Diane Pennica, Luca Rastelli, Bruce Tallion
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090186363
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 11, 2009
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • Apo-2 ligand
    Publication number: 20090186812
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090186409
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 29, 2007
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi S. Philips, Paul Polakis, Victoria Smith, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20090186018
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Alex Abbas, Sarah C. Bodary-Winter, Hilary Clark, Jill R. Schoenfeld, William I. Wood, Thomas D. Wu
  • Heregulin variants
    Patent number: 7563583
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-?1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: July 21, 2009
    Assignee: Genentech, Inc.
    Inventors: Marcus D Ballinger, Jennifer T Jones, Wayne J Fairbrother, Mark S Sliwkowski, James A Wells
  • PRO4356 polypeptides
    Patent number: 7563867
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: July 21, 2009
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Jian Chen, Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • HUMANIZED ANTI-CD40 ANTIBODIES AND THEIR METHODS OF USE
    Publication number: 20090181015
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: May 26, 2006
    Publication date: July 16, 2009
    Applicants: SEATTLE GENETICS, INC., GENENTECH, INC.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina